News

On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Milos Miljkovic, MD MSc of the National Cancer Institute Center for Cancer Research discusses the main differences between these types of ALCL, how they are diagnosed, and typical frontline therapies.

On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).

Krish Patel, MD of the Swedish Cancer Institute discusses how MRD is measured and what patients should know about testing for it.

LRF grantee Jason Romancik, MD of the Winship Cancer Institute discusses these treatment options and what factors patients should consider when deciding what's right for them.

LRF grantee Natalie Grover, MD of The University of North Carolina at Chapel Hill discusses the evolution of treatments in the past several years and the effect it has had on patients diagnosed with HL.

LRF grantee Christina Lee, MD of the Memorial Sloan Kettering Cancer Center discusses the oral therapies that are currently under investigation for the treatment of frontline MCL and how this could help improve the treatment landscape for these patients.